Only Hyperuricemia with Crystalluria, but not Asymptomatic Hyperuricemia, Drives Progression of Chronic Kidney Disease

Только гиперурикемия с кристаллурией, но не бессимптомная гиперурикемия, обусловливает прогрессирование хронической болезни почек
Julio Sáez-Rodríguez, Paola Romagnani, Rafael Kramann, Maria Lucia Angelotti, Hans‐Joachim Anders, Helen Liapis, Hyojin Kim, Nils Krüger, Qiuyue Ma, Stefanie Steiger, Maciej Lech, Markus Sellmayr, Christoph Kuppe, Moritz Roman Hernández Petzsche, Andreas Brink, Barbara F. Lenz, Viviane Gnemmi, Eric Moniqué Johannes Bindels, Ferenc Tajti
2020-09-16

M1-like macrophagesasymptomatic hyperuricemiachronic kidney diseasegranulomatous interstitial nephritisuric acid crystalluria
Significance Statement The role of asymptomatic hyperuricemia in the progression of CKD has been unclear due to lack of animal models with clinically relevant uric acid (UA) levels. A new mouse model reveals that persistent asymptomatic hyperuricemia (approximately 15 mg/dl) does not cause CKD, nor accelerate progression, unless UA crystallizes in acidic tubular fluid. Crystallization initially causes tubular injury, inflammation, and interstitial fibrosis, and subsequently granulomatous interstitial nephritis with perilesional proinflammatory M1-like macrophage infiltrates. Modulating the M1-like macrophage phenotype, but not JAK/STAT inhibition, attenuates granulomatous nephritis. Background The roles of asymptomatic hyperuricemia or uric acid (UA) crystals in CKD progression are unknown. Hypotheses to explain links between UA deposition and progression of CKD include that ( 1 ) asymptomatic hyperuricemia does not promote CKD progression unless UA crystallizes in the kidney; ( 2 ) UA crystal granulomas may form due to pre-existing CKD; and ( 3 ) proinflammatory granuloma-related M1-like macrophages may drive UA crystal-induced CKD progression. Methods MALDI-FTICR mass spectrometry, immunohistochemistry, 3D confocal microscopy, and flow cytometry were used to characterize a novel mouse model of hyperuricemia and chronic UA crystal nephropathy with granulomatous nephritis. Interventional studies probed the role of crystal-induced inflammation and macrophages in the pathology of progressive CKD. Results Asymptomatic hyperuricemia alone did not cause CKD or drive the progression of aristolochic acid I-induced CKD. Only hyperuricemia with UA crystalluria due to urinary acidification caused tubular obstruction, inflammation, and interstitial fibrosis. UA crystal granulomas surrounded by proinflammatory M1-like macrophages developed late in this process of chronic UA crystal nephropathy and contributed to the progression of pre-existing CKD. Suppressing M1-like macrophages with adenosine attenuated granulomatous nephritis and the progressive decline in GFR. In contrast, inhibiting the JAK/STAT inflammatory pathway with tofacitinib was not renoprotective. Conclusions Asymptomatic hyperuricemia does not affect CKD progression unless UA crystallizes in the kidney. UA crystal granulomas develop late in chronic UA crystal nephropathy and contribute to CKD progression because UA crystals trigger M1-like macrophage-related interstitial inflammation and fibrosis. Targeting proinflammatory macrophages, but not JAK/STAT signaling, can attenuate granulomatous interstitial nephritis.
1
CKD progression occurred only when urinary acidification caused uric acid crystallization, producing tubular obstruction, inflammation, and interstitial fibrosis.
2
Modulating the M1-like macrophage phenotype attenuated granulomatous nephritis, whereas JAK/STAT inhibition did not.
3
Persistent asymptomatic hyperuricemia at approximately 15 mg/dl neither caused CKD nor accelerated aristolochic acid I-induced CKD progression in mice.
4
The findings support renal uric acid crystallization, rather than asymptomatic hyperuricemia alone, as the driver of progressive crystal-associated CKD.
5
Uric acid crystal granulomas developed later, were surrounded by proinflammatory M1-like macrophages, and contributed to progression of pre-existing CKD.

A mouse model of persistent hyperuricemia with uric acid crystalluria and chronic uric acid crystal nephropathy, including pre-existing CKD

The effects and mechanisms of uric acid crystallization, tubular injury, granulomatous inflammation, M1-like macrophage responses, and CKD progression

Publication Details
Publication Date
2020-09-16
Journal
Publisher
ISSN
Cited by
147
Access Type
Author Information
Authors
Julio Sáez-Rodríguez
Paola Romagnani
Rafael Kramann
Maria Lucia Angelotti
Hans‐Joachim Anders
Helen Liapis
Hyojin Kim
Nils Krüger
Qiuyue Ma
Stefanie Steiger
Maciej Lech
Markus Sellmayr
Christoph Kuppe
Moritz Roman Hernández Petzsche
Andreas Brink
Barbara F. Lenz
Viviane Gnemmi
Eric Moniqué Johannes Bindels
Ferenc Tajti
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%